Posts tagged “Biotech & Life Science”

Updated August 20, 2007

Premium Lock N.C. Biotech Center CEO Norris Tolson Headlines ‘The Exchange’

Merger logo WRAL Local Tech Wire’s networking event for executives is set for Sept. 12.

August 16, 2007

Premium Lock Parion Sciences Signs Drug Development Deal with Gilead Sciences

Parion  Parion receives $5 million license payment for drug rights. Gilead also invests $5 million in Durham-based startup.

August 15, 2007

Premium Lock Class Action Complaint ‘Completely Without Merit,’ Pozen Says

Pozen Three law firms have announced suits against Pozen after FDA rejected drug.

August 15, 2007

Premium Lock Campbell Alliance Opens Office in Atlanta

Raleigh-based consulting firm has added four offices in past year.

August 15, 2007

Premium Lock NC Health Information Group Unveils Mobile Security Template

NCHICA Document spells out procedures, policies for protecting health information.

Updated August 14, 2007

Premium Lock Icagen Lands Potential $1 Billion Deal with Pfizer

Icagen Update: Drug giant to invest up to $15M in Icagen stock. Development of three products could produce $359M each. Pfizer also makes $12M upfront payment.

August 13, 2007

Premium Lock Inspire Launches Sale of Eye Treatment Drug

Inspire Durham company licensed rights to AzaSite for $32 million.

August 13, 2007

Premium Lock FDA Rejects Solvay-Wyeth Drug Targeting Schizophrenia

FDA Companies plan to continue to seek approval of bifeprunox.

August 9, 2007

Premium Lock Trimeris Reports Another Profit, But Stock Falls 11% in After-Hours Trading

Trimeris Major stockholder requests meeting with management. Trimeris also discloses plans to advance HIV drug candidate to clinical trials.

Updated August 9, 2007

Premium Lock N.C. Biotech Center Awards $822,000 in Grants to 11 Scientists

Biotech Center Grant program is designed to help researchers move toward commercialization of discoveries.

August 8, 2007

Premium Lock Inspire Shares Jump 9% on Earnings News

Inspire Company’s revenues and size of losses top Street expectations.

August 8, 2007

Premium Lock FDA Rejects GSK Bid for New Dosage of Emphysema Drug

GlaxoSmithKline Setback is second in less than two weeks for a big-selling GSK product. FDA recently required stronger warnings on GSK diabetes drug.

Updated August 8, 2007

Premium Lock Trimeris Extends Contracts with Several Top Executives

Trimeris Interim president hired in March could stay in place through 2008 at $450 per hour.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith